Transparency Market Research (TMR) (www.transparencymarketresearch.com) has published a new report titled, “Pediatric Neuroblastoma Treatment Market – Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2018–2026.” According to the report, the global pediatric neuroblastoma treatment market is projected to reach US$ 1.3 Bn by 2026 at a considerable CAGR from 2018 to 2026. North America is anticipated to dominate the global market during the forecast period due to high incidence of neuroblastoma.

Chemotherapy Segment to Dominate Market

The report offers detailed segmentation of the global pediatric neuroblastoma treatment market based on therapy type and distribution channel. In terms of therapy type, the global market has been segmented into immunotherapy, chemotherapy, and others. The chemotherapy segment held the leading market share in 2017. The segment is projected to expand at the highest CAGR during the forecast period. This is attributed to effectiveness of chemotherapy drugs in neuroblastoma treatment.

Hospital Pharmacies Segment Held Major Market Share in 2017

Based on distribution channel, the global pediatric neuroblastoma treatment market has been classified into hospital pharmacies and retail pharmacies & drug stores. The hospital pharmacies segment dominated the market in 2017 and is expected to sustain its leadership position in terms of market share during the forecast period. This is due to high preference for hospital pharmacies for purchasing drugs prescribed for cancer treatment.

Request a PDF Brochure For the Pediatric Neuroblastoma Treatment Market  Report @ https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=37835

North America Market to Expand at High CAGR

According to American Cancer Society’s Cancer Statistics, nearly 800 new cases of neuroblastoma are reported in the U.S. each year. This number has been stagnant for several years. Moreover, high cost of therapy, technologically advanced products, improved health care infrastructure, and better reimbursement plans are the major factors contributing to the region’s dominance of the global market.

Competition Landscape

Major players operating in the global pediatric neuroblastoma treatment market are United Therapeutics Corporation, APEIRON Biologics AG, Baxter, Cellectar Biosciences, Inc., Pfizer, Inc., MacroGenics, Inc., and Bayer AG. These players are expanding their product portfolios through mergers and acquisitions and partnerships & collaborations with leading pharmaceutical and biotechnology companies, and by offering technologically advanced products.

Important queries related to the keyword market addressed in the report:

• What is the projected value of the keyword market in 2029?
• In which region is the concentration of tier 1 companies the highest?
• How have the evolving regulatory policies influenced the growth of the keyword market?
• How are market players expanding their footprint in the global keyword market?
• Which end-use is expected to dominate the keyword market in terms of share and demand?

Why Choose TMR?

• Unbiased conclusions and market insights
• 24×7 customer service available to address client queries
• Highly efficient and experienced team of analysts striving to create top-quality reports
• Our reports have facilitated the growth of over 500 companies
• A systematic and methodical market research process